Media & Press

For media inquiries, please contact phenomix@ampublicrelations.com

MAYO CLINIC JOINS OBESITY BIOBANKING REGISTRY, STUDY

By Eric Wicklund
July 26, 2022
 
The Minnesota-based health system is taking part in a massive data-gathering project aimed at understanding how to diagnose and treat obesity.

 

KEY TAKEAWAYS

  • Obesity affects roughly 42 percent of the American population, is a precursor to a wide range of chronic conditions and accounts for roughly $480 billion in healthcare spending each year.
  • The Mayo Clinic and Phenomix Sciences are partnering on a biobanking registry aimed at collecting data from patients dealing with obesity and a national study to monitor phenotypes in patients undergoing treatments for obesity.
  • Continue reading...

VIDEO: Brain-gut communication and its role in food intake, obesity epidemic

By Kate Burba in Healio Gasterenterology

June 4, 2022

SAN DIEGO — In a Healio video exclusive, Andres Acosta, MD, PhD, outlines research presented at Digestive Disease Week 2022 that focused on the relationship between gastric function and the regulation of food intake.

“Our research mainly focuses on understanding how the gut communicates with the brain to regulate food intake. This is extremely important because we are suffering an obesity epidemic,” Acosta, assistant professor of medicine and consultant in gastroenterology and hepatology at Mayo Clinic, said. “We're super excited to explain how our gut communicates with the brain, regulates food intake and plays a major role in obesity and in the pathophysiology of a disease that is really affecting our epidemic.” Watch here...


Phenomix Launches The First Obesity Biobank Registry To Study Underling Phenotypes

by Joy Lin in Gene Online

May 26, 2022

On a mission to conquer obesity, Phenomix Sciences has launched its first obesity biobanking registry and outcomes study. The registry will study variability in obesity by looking at genetic and environmental factors in patients, and analyze interventions that will give maximum benefit to the individual patient. Continue reading...


Phenomix Sciences Announces First Precision Obesity Biobanking Registry and Outcomes Study

May 25, 2022

Mayo Clinic first to enroll in registry with study of 2,000 patients being treated for obesity

ST. PAUL, Minn., May 25, 2022 /PRNewswire/ -- Phenomix Sciences (Phenomix), a precision obesity biotechnology company, announces today the launch of its biobanking registry and outcomes study. The registry will evaluate variability in obesity treatment response by collecting patients' DNA, metabolomics, hormones, and behavioral assessments, in relation to treatment outcomes. Continue Reading...


Phenomix Sciences Signs Exclusive Technology Licensing Deal With Mayo Clinic for Obesity Phenotype Blood Test

May 4, 2021

ST. PAUL, Minn.--(BUSINESS WIRE)--Biomedical startup company Phenomix Sciences (Phenomix) has signed an exclusive technology licensing agreement with Mayo Clinic for a novel blood test that accurately predicts obesity phenotypes. The multi-level “omics” MyPhenome™ test leverages technology developed at Mayo Clinic to analyze genomics, metabolomics and hormone levels. Its AI-driven algorithmic solution identifies four specific obesity phenotypes to give doctors the ability to prescribe more precise anti-obesity treatments. With the finalization of the CLIA lab underway, Phenomix anticipates launching the MyPhenome™ test before the end of 2021. Continue Reading...


PHENOMIX AND MAYO CLINIC DETERMINE OBESITY RISK THROUGH PHENOTYPES

July 1, 2021

Using one patient blood sample, the MyPhenome test developed by Mayo Clinic employs an artificial intelligence-based algorithm to analyze a patient’s DNA as well as metabolomic and hormone markers related to obesity. The companies expect it to help clinicians provide earlier diagnosis and better anti-obesity treatment options, including drugs, devices, or surgeries, by analyzing the phenotypes identified from the test. Continue Reading...


Phenomix Sciences taps Mayo Clinic tech for AI-powered obesity diagnostic

May 5, 2021

In aMayo Clinic logo shift from traditional thinking that lumps together all cases of obesity, researchers are increasingly proving that a combination of genetic and environmental factors have resulted in several distinct forms of the condition, each requiring a different treatment.  Continue Reading...


Phenomix, Mayo Clinic Ink Licensing Deal for Obesity Phenotype Blood Test 

May 4, 2021

NEW YORK – Biomedical startup company Phenomix Sciences said on Tuesday that it has signed an exclusive technology licensing agreement with the Mayo Clinic for a blood test to predict obesity phenotypes. Financial and other terms of the deal were not disclosed. The multiomics MyPhenome test uses technology developed at the Mayo Clinic to analyze a person's genomic, metabolomic, and hormone profile, and uses artificial intelligence-driven algorithms to identify which one of four specific obesity phenotypes the person fits: Hungry Brain, a defect of satiation; Hungry Gut, a defect of satiety; Emotional Hunger, emotional reward from eating; or Slow Burn, a defect in energy expenditure. Continue Reading...


Q&A: How new blood testing could help doctors better treat obesity

May 3, 2021

Phenomix Sciences was founded by National Institutes of Health (NIH)-funded obesity experts and Mayo Clinic physician-scientists Andres Acosta, MD, PhD, and Michael Camilleri, MD, in Rochester, Minnesota, in 2017. Health2047, the wholly-owned innovation subsidiary of the AMA created to overcome systemic dysfunction in the U.S. health care, recently launched the company. Continue Reading...


Novel obesity classifications can aid in tailoring weight-loss treatments

April 28, 2021

Phenotype-guided obesity interventions, determined by a blood test, can double weight loss for patients compared with standard obesity care, according to a presenter at the Obesity Medicine Association 2021 virtual conference.


Health2047 Spins Out Obesity Testing Company Phenomix Sciences

March 22, 2021

MENLO PARK, Calif.--(BUSINESS WIRE)--Health2047 Inc., the Silicon Valley-based innovation subsidiary of the American Medical Association (AMA), today announced the spin out of Phenomix Sciences (Phenomix), a phenotype testing company whose AI-derived test analyzes genomics, metabolomics and hormone levels to deliver a new personalized measure for obesity that enhances treatment outcomes. Phenomix provides a solution that identifies four specific obesity phenotypes; the company’s MyPhenomeTM test gives doctors the ability to prescribe individualized anti-obesity therapies that are more effective. Continue Reading...


AMA unit Health2047 spins out obesity testing startup to accelerate personalized medicine

April 1, 2021

The American Medical Association innovation subsidiary Health2047 has spun off a company that uses personalized medicine to fight obesity. Phenomix Sciences is a phenotype testing company that carries out the AMA’s mission to confront chronic diseases such as obesity. Phenomix uses a blood test called MyPhenome that it has licensed from the Mayo Clinic to allow doctors to prescribe individualized therapies. MyPhenome measures DNA as well as a person’s metabolites and hormones. These biomarkers make up a person’s phenotype, according to Phenomix. Continue Reading...